Why the study?
Previous studies on angiotensin converting enzyme (ACE) insertion/deletion (I/D) genetic polymorphism and glioma risk were inconsistent.
Is the angiotensin converting enzyme (ACE) insertion/deletion (I/D) genetic polymorphism associated with glioma risk?
Is the angiotensin converting enzyme (ACE) insertion/deletion (I/D) genetic polymorphism associated with glioma risk?
This meta-analysis found no evidence that ACE I/D genetic polymorphisms are associated with glioma susceptibility or clinical grade.
OBJECTIVE: The previous studies on angiotensin converting enzyme (ACE) insertion/deletion (I/D) genetic polymorphism and glioma risk were inconsistent. Therefore, we performed a meta-analysis to assess the association between ACE I/D polymorphisms and glioma risk. METHODS AND RESULTS: In total, four populations (1110 cases and 1335 controls) on ACE I/D polymorphism were included. Overall, the meta-analysis demonstrated no significant association between ACE I/D polymorphism and glioma risk. In addition, the analysis of the association of ACE I/D polymorphism and clinical grade also showed no significant association. CONCLUSION: Our meta-analysis didn't find a significant association between ACE I/D polymorphism glioma risk. However, further studies with larger sample size and more ethnic groups are required to confirm the results.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: